Larimar Therapeutics, Inc.

DB:ZA71 Stock Report

Market Cap: €407.9m

Larimar Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Larimar Therapeutics has a total shareholder equity of $211.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $237.2M and $25.8M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$226.06m
EquityUS$211.40m
Total liabilitiesUS$25.76m
Total assetsUS$237.16m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: ZA71's short term assets ($231.1M) exceed its short term liabilities ($21.2M).

Long Term Liabilities: ZA71's short term assets ($231.1M) exceed its long term liabilities ($4.6M).


Debt to Equity History and Analysis

Debt Level: ZA71 is debt free.

Reducing Debt: ZA71 has no debt compared to 5 years ago when its debt to equity ratio was 4.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZA71 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ZA71 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 4.8% each year.


Discover healthy companies